Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• The standard starting dose of Tolvaptan for heart failure (HF) is 7.5 mg/day in Japan, with a lower dose of 3.75 mg/day recommended for older patients to prevent adverse effects.
• However, the efficacy of the 3.75 mg/day dose may be limited in some patients, potentially delaying congestion relief.

Purpose of the Study:

• To develop and validate a predictive score to identify patients likely to respond to a 3.75 mg/day dose of Tolvaptan.
• To aid in determining the optimal initial Tolvaptan dosage for older heart failure patients, balancing efficacy and safety.

Main Methods:

• Retrospective analysis of 106 patients (derivation cohort) and 63 patients (validation cohort) with HF receiving 3.75 mg/day of Tolvaptan.
• Multivariate analysis identified blood urea nitrogen (BUN) < 39 mg/dL and hematocrit > 35% as predictors of response.
• A scoring system was created, stratifying patients into groups based on 0, 1, or 2 points.

Main Results:

• The score demonstrated significant predictive ability for treatment response (AUC 0.726 in derivation, 0.733 in validation).
• Patients with a higher score (2 points) showed a higher response rate (82.9%) compared to those with lower scores (61.5% for 1 point, 34.4% for 0 points).
• Treatment responders were defined as patients not requiring Tolvaptan dose escalation for congestion relief.

Conclusions:

• A simple score utilizing BUN and hematocrit effectively predicts response to 3.75 mg Tolvaptan in heart failure patients.
• This score can assist clinicians in selecting the appropriate starting dose of Tolvaptan for older patients, optimizing treatment efficacy while minimizing risks.